Literature DB >> 32076894

Bayesian Individual Dynamic Predictions with Uncertainty of Longitudinal Biomarkers and Risks of Survival Events in a Joint Modelling Framework: a Comparison Between Stan, Monolix, and NONMEM.

François Riglet1, France Mentre2, Christine Veyrat-Follet3, Julie Bertrand2.   

Abstract

Given a joint model and its parameters, Bayesian individual dynamic prediction (IDP) of biomarkers and risk of event can be performed for new patients at different landmark times using observed biomarker values. The aim of the present study was to compare IDP, with uncertainty, using Stan 2.18, Monolix 2018R2 and NONMEM 7.4. Simulations of biomarker and survival were performed using a nonlinear joint model of prostate-specific antigen (PSA) kinetics and survival in metastatic prostate cancer. Several scenarios were evaluated, according to the strength of the association between PSA and survival. For various landmark times, a posteriori distribution of PSA kinetic individual parameters was estimated, given individual observations, with each software. Samples of individual parameters were drawn from the posterior distribution. Bias and imprecision of individual parameters as well as coverage of 95% credibility interval for PSA and risk of death were evaluated. All software performed equally well with small biases on individual parameters. Imprecision on individual parameters was comparable across software and showed marked improvements with increasing landmark time. In terms of coverage, results were also comparable and all software were able to well predict PSA kinetics and survival. As for computing time, Stan was faster than Monolix and NONMEM to obtain individual parameters. Stan 2.18, Monolix 2018R2 and NONMEM 7.4 are able to characterize IDP of biomarkers and risk of event in a nonlinear joint modelling framework with correct uncertainty and hence could be used in the context of individualized medicine.

Entities:  

Keywords:  Bayesian; individual predictions; joint model; nonlinear mixed effect model

Mesh:

Substances:

Year:  2020        PMID: 32076894     DOI: 10.1208/s12248-019-0388-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  21 in total

1.  Estimation and comparison of rates of change in longitudinal studies with informative drop-outs.

Authors:  G Touloumi; S J Pocock; A G Babiker; J H Darbyshire
Journal:  Stat Med       Date:  1999-05-30       Impact factor: 2.373

2.  Assessment and comparison of prognostic classification schemes for survival data.

Authors:  E Graf; C Schmoor; W Sauerbrei; M Schumacher
Journal:  Stat Med       Date:  1999 Sep 15-30       Impact factor: 2.373

3.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

4.  Missing data in model-based pharmacometric applications: points to consider.

Authors:  Marc R Gastonguay; Jonathan L French; Daniel F Heitjan; James A Rogers; Jae Eun Ahn; Patanjali Ravva
Journal:  J Clin Pharmacol       Date:  2010-09       Impact factor: 3.126

5.  Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

Authors:  Laurent Claret; Pascal Girard; Paulo M Hoff; Eric Van Cutsem; Klaas P Zuideveld; Karin Jorga; Jan Fagerberg; René Bruno
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

6.  Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.

Authors:  Solène Desmée; France Mentré; Christine Veyrat-Follet; Jérémie Guedj
Journal:  AAPS J       Date:  2015-03-05       Impact factor: 4.009

7.  The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.

Authors:  Phylinda L S Chan; Philippe Jacqmin; Marc Lavielle; Lynn McFadyen; Barry Weatherley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-19       Impact factor: 2.745

8.  Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients.

Authors:  Solène Desmée; France Mentré; Christine Veyrat-Follet; Bernard Sébastien; Jérémie Guedj
Journal:  Biometrics       Date:  2016-05-05       Impact factor: 2.571

Review 9.  Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis.

Authors:  Maria Sudell; Ruwanthi Kolamunnage-Dona; Catrin Tudur-Smith
Journal:  BMC Med Res Methodol       Date:  2016-12-05       Impact factor: 4.615

10.  A Joint Model for the Kinetics of CTC Count and PSA Concentration During Treatment in Metastatic Castration-Resistant Prostate Cancer.

Authors:  M Wilbaux; M Tod; J De Bono; D Lorente; J Mateo; G Freyer; B You; E Hénin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-04-24
View more
  3 in total

1.  Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab.

Authors:  Sergey Gavrilov; Kirill Zhudenkov; Gabriel Helmlinger; James Dunyak; Kirill Peskov; Sergey Aksenov
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-12-21

2.  A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnostics.

Authors:  Kirill Zhudenkov; Sergey Gavrilov; Alina Sofronova; Oleg Stepanov; Nataliya Kudryashova; Gabriel Helmlinger; Kirill Peskov
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-02-21

3.  Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel.

Authors:  Sreenath M Krishnan; Lena E Friberg; René Bruno; Ulrich Beyer; Jin Y Jin; Mats O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.